Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
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
9XEpgweK9GE5dNMj
